Source comparison
Best Thymosin Alpha-1 Dosage for Immune Modulation: Research Peptide Comparison
Thymosin Alpha-1 TLR-2/TLR-9 agonist; dendritic cell maturation; Th1/Th2 balance 1.6–6.4mg SC, 2–3×/week Broad-spectrum T-cell enhancement; viral suppression; autoimmune rebalancing Most versatile immune modulator with dose-dependent effects. Low-dose sustaine
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR-2/TLR-9 agonist; dendritic cell maturation; Th1/Th2 balance
- 1.6–6.4mg SC, 2–3×/week
- Broad-spectrum T-cell enhancement; viral suppression; autoimmune rebalancing
- Most versatile immune modulator with dose-dependent effects. Low-dose sustained for chronic use, high-dose short-term for acute intervention
- Thymalin
- Thymic epithelial extract; multi-peptide complex
- 5–10mg IM daily for 10 days
- Thymic regeneration; age-related immune decline
- Broader thymic support than Tα1 but less targeted. Better for generalised immunosenescence than specific viral suppression
- TB-500 (Thymosin Beta-4)
- Actin-binding protein; promotes cell migration
- 2–5mg SC, 2×/week
- Tissue repair; anti-inflammatory; indirect immune support via wound healing
- Not a direct immune modulator. Enhances tissue recovery which secondarily reduces immune burden
- LL-37 (Cathelicidin)
- Antimicrobial peptide; direct pathogen membrane disruption
- 2–4mg SC, 3×/week
- Innate immunity; bacterial/viral membrane lysis
- Immediate antimicrobial action but no adaptive immune enhancement. Complements Tα1 in acute infection but doesn't replace it
- BPC-157
- Angiogenesis; NO pathway modulation
- 250–500mcg SC daily
- Mucosal immune barrier repair; gut-associated lymphoid tissue (GALT) support
- Restores mucosal immunity (critical for microbiome-immune axis) but lacks systemic T-cell modulation